OptiNose (OPTN) expects to raise $101 million in an initial public offering (IPO) on Friday, October 13th, IPO Scoop reports. The company will be issuing 6,300,000 shares at $15.00-$17.00 per share.

The company has a market cap of $566.2 million.

Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose provided the following description of their company for its IPO: “We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. Our lead product, XHANCE, is a therapeutic utilizing our proprietary Breath Powered exhalation delivery system, or EDS, that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. “.

OptiNose was founded in 2010 and has 35 employees. The company is located at 1020 Stony Hill Road, Suite 300, Yardley, Pennsylvania 19067 and can be reached via phone at (267) 364-3500 or on the web at http://www.optinose.com.

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with Analyst Ratings Network's FREE daily email newsletter.